Story Highlight
– 10 million Brits risk addiction to over-the-counter painkillers.
– One in six use codeine for over nine days.
– Codeine sales often exceed recommended guidelines.
– Users “pharmacy hop” to obtain more painkillers.
– Prolonged use risks serious health complications.
Full Story
Approximately 10 million individuals in the UK may be at risk of developing an addiction to over-the-counter pain relief medications containing codeine, according to a recent survey and investigation. Medical experts are increasingly alarmed about the potential for a growing dependency crisis linked to the non-prescription availability of these medications.
Common preparations, such as co-codamol—a painkiller combining paracetamol and codeine—are readily accessible via pharmacies without a doctor’s prescription. Despite regulations stipulating that these products should only be sold in limited quantities (a maximum of 32 tablets at a time) and for short-term use (not exceeding three days), findings from an ITV investigation reveal widespread non-compliance with these guidelines.
In a survey involving over 2,000 adults in the UK, it was reported that around 16% of respondents using non-prescription codeine consumed the painkiller for periods extending to nine days. Alarmingly, one in five participants admitted to using the medication for more than ten days, which significantly increases the risk of developing both a dependency and possible addiction.
Medical professionals highlight that prolonged use beyond the recommended duration can lead to physical dependence on codeine. The drug, an opioid, can alter the way the nervous system responds to pain, causing the body to adapt over time. As a result, individuals may find they require higher doses to achieve the same level of pain relief, posing issues of tolerance and addiction in the long term.
The investigation by ITV has drawn broader concerns to light, indicating that misuse of non-prescription drugs isn’t limited to codeine. There is also evidence suggesting that users are mismanaging sleeping aids and nasal sprays, both of which carry risks of addiction when used incorrectly.
The accessibility of codeine in the UK starkly contrasts with regulations in 25 other countries, including Australia. Following a regulatory change in 2018, the availability of over-the-counter codeine was significantly restricted in these nations to mitigate abuse and addiction risks.
Individuals like Abby House have shared personal accounts of how easily accessible painkillers have adversely affected their lives. Following a prescription for codeine after undergoing gastric sleeve surgery, Abby transitioned to using over-the-counter products, leading her down a path of addiction. “I was buying at least 20 boxes a week, I’d say. I was taking so much that it was making me sick,” she recounted. “There were 224 put on my repeat prescription. I would take those at my worst in about two to three days. I went into £8,000 worth of debt and I was using the money that I needed to pay my bills and my car insurance.”
The current regulations permit only one pack of codeine-containing painkillers to be sold at a time from a pharmacy. Pharmacists are tasked with cautioning buyers about the three-day limit and can refuse sales if they suspect abuse. However, many individuals struggling with addiction resort to “pharmacy hopping.” One user revealed that she would visit multiple pharmacies to buy a single pack, avoiding detection. Others have found it equally easy to navigate online platforms to procure the drugs without raising any flags.
The ease of acquiring these painkillers has been highlighted as a significant factor in prolonging addiction. A former NHS employee, now in recovery, reflected that the simplicity of purchasing over-the-counter painkillers contributed to her prolonged struggle with codeine addiction. “I believe [the ease of buying over-the-counter painkillers] kept me in addiction for three years longer than I needed to be,” she remarked.
The implications of continuous use of codeine-containing medications extend beyond addiction. The additional ingredients, such as paracetamol and ibuprofen, pose a risk of severe physical damage. Regular overuse can lead to complications such as stomach ulcers, perforation, liver damage, and kidney issues.
In response to these disturbing trends, the Department of Health and Social Care stated, “All over-the-counter medicines are kept under continuous review, and action is taken where evidence of harm emerges, including updating packaging and safety information or changing how medicines are supplied.” Meanwhile, the Consumer Healthcare Association has urged patients to read safety information closely and adhere to usage guidelines provided.
In a related concern, the Medicines and Healthcare products Regulatory Agency (MHRA) recently issued a warning regarding decongestant nasal sprays. They highlighted the potential for users to unknowingly develop an addiction to these products, which could lead to irreversible airway damage.
As the UK grapples with the implications of over-the-counter codeine availability, it is becoming evident that stricter regulations and greater awareness are essential to mitigate the risks of addiction and ensure public health is safeguarded. The ongoing conversation among healthcare experts, lawmakers, and the public about responsible medication use will play a crucial role in addressing this pressing issue.
Our Thoughts
To avoid the addiction risks associated with over-the-counter codeine painkillers, several key actions could be implemented based on UK Health and Safety legislation. First, stricter regulations on the sale of codeine-based products could be enacted, similar to those in Australia, which may involve limiting sales to pharmacies only after a thorough screening process.
Pharmacists must adhere to guidelines that limit sales to a maximum of 32 tablets for no more than three days. They should be trained to recognize signs of dependency and have protocols in place to refuse sales to individuals displaying such behaviors. Increased awareness campaigns could inform the public about the dangers of prolonged use and dependency, encouraging responsible use and adherence to safety information provided.
The situation highlights breaches of the UK guidance on the sale of these medications, particularly if individuals are allowed to “pharmacy hop” without restriction. Implementing an electronic monitoring system for sales could help track purchases across multiple pharmacies, thus preventing abuse.
Finally, regular reviews of over-the-counter medications by the Medicines and Healthcare products Regulatory Agency (MHRA) are essential to identify potential risks early and modify access and labeling to safeguard public health.
